Nifty
:
13967.50
Sensex
:
47409.93
-271.40 (-1.91%)
-937.66 (-1.94%)
Nifty
Sensex
:
:
13967.50
47409.93
-271.40 (-1.91%)
-937.66 (-1.94%)

Pharmaceuticals & Drugs

Rating :
59/99  (View)

BSE: 500009 | NSE: AMBASARABH

NSE BSE
20.50
-0.45 (-2.15%)
27-Jan-2021 | 4:01PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  20.95
  •  21.50
  •  20.10
  •  20.95
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  40025
  •  8.21
  •  30.95
  •  12.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 160.55
  • 6.39
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 169.01
  • N/A
  • 3.37

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 30.76%
  • 20.46%
  • 46.22%
  • FII
  • DII
  • Others
  • 0%
  • 0.00%
  • 2.56%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.32
  • 0.23
  • 2.22

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -20.83
  • -31.60
  • -30.53

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -20.34
  • 142.70

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 1.61
  • 18.46

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.93
  • 2.88
  • 3.83

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.51
  • 0.83
  • 1.75

Quarterly Results

Consolidated Figures in Rs. Crores /

Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
42.42
32.27
31.45%
26.72
30.95
-13.67%
38.56
44.78
-13.89%
31.71
36.74
-13.69%
Expenses
39.07
32.84
18.97%
26.62
32.25
-17.46%
37.19
42.00
-11.45%
33.40
34.53
-3.27%
EBITDA
3.35
-0.57
-
0.10
-1.31
-
1.37
2.78
-50.72%
-1.69
2.21
-
EBIDTM
7.89%
-1.76%
0.38%
-4.22%
3.55%
6.21%
-5.33%
6.01%
Other Income
2.14
2.23
-4.04%
1.55
2.89
-46.37%
15.93
1.86
756.45%
3.35
1.28
161.72%
Interest
0.78
0.99
-21.21%
0.82
0.93
-11.83%
0.85
0.57
49.12%
0.55
1.18
-53.39%
Depreciation
0.59
0.50
18.00%
0.65
0.51
27.45%
1.03
0.54
90.74%
0.52
0.53
-1.89%
PBT
4.12
0.17
2,323.53%
0.19
0.15
26.67%
15.41
3.53
336.54%
0.58
1.78
-67.42%
Tax
0.97
-0.12
-
0.40
-0.04
-
1.10
2.49
-55.82%
-0.07
0.05
-
PAT
3.15
0.29
986.21%
-0.22
0.19
-
14.31
1.04
1,275.96%
0.65
1.73
-62.43%
PATM
7.42%
0.88%
-0.82%
0.61%
37.11%
2.32%
2.05%
4.70%
EPS
1.41
0.01
14,000.00%
0.12
0.08
50.00%
1.69
0.15
1,026.67%
0.06
0.35
-82.86%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
139.41
133.50
151.88
125.00
133.88
131.98
124.50
104.65
100.24
88.98
79.51
Net Sales Growth
-3.68%
-12.10%
21.50%
-6.63%
1.44%
6.01%
18.97%
4.40%
12.65%
11.91%
 
Cost Of Goods Sold
81.59
79.34
89.52
70.20
76.92
72.88
72.73
58.10
54.18
51.56
50.14
Gross Profit
57.82
54.16
62.36
54.81
56.95
59.11
51.76
46.55
46.07
37.42
29.37
GP Margin
41.47%
40.57%
41.06%
43.85%
42.54%
44.79%
41.57%
44.48%
45.96%
42.05%
36.94%
Total Expenditure
136.28
135.40
145.99
136.74
144.95
144.67
128.83
113.27
110.61
101.33
99.15
Power & Fuel Cost
-
2.71
3.22
2.84
2.68
3.67
2.80
2.36
2.97
2.11
2.23
% Of Sales
-
2.03%
2.12%
2.27%
2.00%
2.78%
2.25%
2.26%
2.96%
2.37%
2.80%
Employee Cost
-
27.06
26.02
26.67
28.71
31.29
28.47
27.39
30.28
26.86
25.66
% Of Sales
-
20.27%
17.13%
21.34%
21.44%
23.71%
22.87%
26.17%
30.21%
30.19%
32.27%
Manufacturing Exp.
-
4.07
5.09
5.18
5.43
7.13
5.53
6.00
5.12
4.53
3.84
% Of Sales
-
3.05%
3.35%
4.14%
4.06%
5.40%
4.44%
5.73%
5.11%
5.09%
4.83%
General & Admin Exp.
-
11.94
10.92
24.21
12.52
13.39
10.03
9.56
8.93
7.09
5.21
% Of Sales
-
8.94%
7.19%
19.37%
9.35%
10.15%
8.06%
9.14%
8.91%
7.97%
6.55%
Selling & Distn. Exp.
-
7.03
7.92
4.86
6.53
6.42
6.08
4.66
4.11
4.12
5.18
% Of Sales
-
5.27%
5.21%
3.89%
4.88%
4.86%
4.88%
4.45%
4.10%
4.63%
6.51%
Miscellaneous Exp.
-
3.26
3.30
2.79
12.16
9.90
3.19
5.18
5.02
5.05
5.18
% Of Sales
-
2.44%
2.17%
2.23%
9.08%
7.50%
2.56%
4.95%
5.01%
5.68%
8.65%
EBITDA
3.13
-1.90
5.89
-11.74
-11.07
-12.69
-4.33
-8.62
-10.37
-12.35
-19.64
EBITDA Margin
2.25%
-1.42%
3.88%
-9.39%
-8.27%
-9.62%
-3.48%
-8.24%
-10.35%
-13.88%
-24.70%
Other Income
22.97
24.39
5.47
25.04
6.22
95.08
12.99
3.01
16.41
4.08
8.74
Interest
3.00
3.61
3.29
3.41
4.77
4.10
9.83
10.93
8.52
9.69
11.30
Depreciation
2.79
2.57
2.10
2.12
4.27
16.54
4.81
3.01
14.02
2.90
2.78
PBT
20.30
16.31
5.97
7.77
-13.90
61.74
-5.98
-19.55
-16.50
-20.86
-24.98
Tax
2.40
0.88
3.97
6.69
4.61
13.61
0.69
0.66
1.48
1.04
3.87
Tax Rate
11.82%
5.40%
66.50%
86.10%
-33.17%
22.04%
-11.54%
-3.38%
-8.97%
-10.75%
-52.58%
PAT
17.89
15.44
2.00
1.08
-18.51
48.14
-6.67
-20.21
-17.97
-10.71
-11.23
PAT before Minority Interest
17.89
15.44
2.00
1.08
-18.51
48.14
-6.67
-20.21
-17.97
-10.71
-11.23
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
12.83%
11.57%
1.32%
0.86%
-13.83%
36.48%
-5.36%
-19.31%
-17.93%
-12.04%
-14.12%
PAT Growth
450.46%
672.00%
85.19%
105.83%
-138.45%
821.74%
67.00%
-12.47%
-67.79%
4.63%
 
Unadjusted EPS
2.34
2.02
0.26
0.14
-2.42
6.28
-0.87
-2.64
-2.35
-1.40
-1.47

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
44.77
30.62
26.52
25.17
38.73
-9.40
-2.16
17.94
36.46
47.38
Share Capital
76.63
76.63
76.63
76.63
76.63
76.63
76.63
76.63
76.63
76.63
Total Reserves
-31.87
-46.01
-50.12
-51.46
-37.90
-86.04
-78.79
-58.69
-40.18
-29.25
Non-Current Liabilities
4.80
8.90
11.39
5.83
12.70
15.43
59.01
17.14
15.99
21.37
Secured Loans
4.54
8.76
11.12
5.11
5.72
5.76
3.20
4.09
3.25
12.62
Unsecured Loans
0.00
0.00
0.00
0.00
0.02
0.00
0.00
0.00
0.00
8.56
Long Term Provisions
3.37
3.80
4.38
5.53
6.75
9.85
55.84
12.33
12.30
0.00
Current Liabilities
133.47
171.32
155.44
124.43
152.51
162.77
154.55
175.34
170.71
171.90
Trade Payables
40.02
46.83
39.76
29.14
26.93
27.54
28.33
21.13
33.31
31.70
Other Current Liabilities
65.86
91.29
80.43
50.08
56.70
91.85
86.32
73.61
65.73
71.01
Short Term Borrowings
23.66
28.76
30.34
35.33
39.50
38.92
36.67
33.45
24.55
0.00
Short Term Provisions
3.92
4.44
4.91
9.88
29.38
4.46
3.22
47.15
47.12
69.19
Total Liabilities
183.03
210.83
193.35
155.43
203.94
168.80
211.40
210.42
223.16
240.65
Net Block
57.46
57.65
59.16
72.25
71.76
90.78
94.32
98.39
111.21
112.22
Gross Block
68.25
65.91
65.36
76.34
138.02
153.64
152.39
154.51
155.91
153.82
Accumulated Depreciation
10.79
8.26
6.20
4.09
66.26
62.86
58.07
56.11
44.69
41.60
Non Current Assets
79.06
94.58
79.79
82.18
91.54
100.43
143.97
105.56
122.72
115.57
Capital Work in Progress
0.41
24.06
13.69
3.44
8.97
0.83
0.21
0.10
0.12
1.12
Non Current Investment
18.12
9.36
5.37
4.83
8.10
0.62
0.78
1.30
2.29
2.23
Long Term Loans & Adv.
2.13
1.98
1.48
1.50
1.95
7.73
48.44
2.79
2.61
0.00
Other Non Current Assets
0.94
1.53
0.10
0.17
0.77
0.48
0.22
2.98
6.48
0.00
Current Assets
103.97
116.26
113.55
73.25
112.40
68.37
67.43
104.85
100.43
125.08
Current Investments
0.00
0.00
0.00
0.00
0.00
0.27
0.15
0.00
0.00
0.00
Inventories
16.45
14.98
14.39
13.81
14.41
17.10
15.13
13.72
12.19
10.15
Sundry Debtors
28.80
34.69
34.13
28.95
30.11
25.29
27.18
27.84
21.91
31.61
Cash & Bank
21.53
23.26
22.07
16.71
16.41
13.85
12.28
7.16
9.46
17.50
Other Current Assets
37.19
15.94
25.29
2.39
51.47
11.86
12.68
56.14
56.87
65.82
Short Term Loans & Adv.
25.94
27.39
17.66
11.38
37.98
11.41
11.18
54.83
55.48
65.82
Net Current Assets
-29.50
-55.06
-41.89
-51.18
-40.11
-94.40
-87.12
-70.48
-70.28
-46.82
Total Assets
183.03
210.84
193.34
155.43
203.94
168.80
211.40
210.41
223.15
240.65

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
-6.88
18.80
-7.39
5.40
-74.99
-8.32
11.02
-3.26
-12.80
-3.29
PBT
14.94
8.21
7.96
-13.62
61.74
-5.98
-19.55
-16.50
-9.67
-11.23
Adjustment
-13.26
1.79
-11.90
17.83
-67.13
2.50
14.47
6.76
-1.90
0.57
Changes in Working Capital
-6.07
16.64
16.46
2.77
-64.49
-0.39
17.76
8.26
8.98
10.53
Cash after chg. in Working capital
-4.40
26.65
12.53
6.98
-69.88
-3.88
12.67
-1.48
-2.60
-0.13
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-2.48
-7.84
-19.93
-1.58
-5.12
-4.44
-1.66
-1.78
-10.21
-3.15
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
16.89
-9.25
17.58
-3.31
80.06
9.80
-0.89
-0.28
10.79
8.25
Net Fixed Assets
-0.23
-0.06
1.03
56.92
20.63
0.40
0.84
2.06
0.91
9.21
Net Investments
2.59
-0.09
8.92
6.72
-26.62
-0.13
1.83
0.50
-1.55
-12.78
Others
14.53
-9.10
7.63
-66.95
86.05
9.53
-3.56
-2.84
11.43
11.82
Cash from Financing Activity
-14.22
-6.07
-2.09
-6.26
-3.44
-0.61
-8.39
2.75
0.65
-4.27
Net Cash Inflow / Outflow
-4.21
3.49
8.10
-4.17
1.62
0.87
1.74
-0.79
-1.36
0.69
Opening Cash & Equivalents
17.00
13.51
5.41
9.58
8.40
7.53
5.79
6.58
7.93
16.81
Closing Cash & Equivalent
12.79
17.00
13.51
5.41
10.03
8.40
7.53
5.79
6.58
17.50

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
5.84
4.00
3.46
3.28
5.05
-1.23
-0.28
2.34
4.76
6.18
ROA
7.84%
0.99%
0.62%
-10.30%
25.83%
-3.51%
-9.58%
-8.29%
-4.62%
-4.86%
ROE
40.95%
7.01%
4.20%
-57.92%
328.25%
0.00%
-256.13%
-66.09%
-25.55%
-21.12%
ROCE
27.36%
13.17%
16.34%
-11.94%
107.14%
10.08%
-17.91%
-12.98%
0.02%
5.56%
Fixed Asset Turnover
2.06
2.34
1.77
1.27
0.93
0.83
0.70
0.66
0.59
0.53
Receivable days
83.82
81.74
91.65
79.06
74.77
75.18
93.62
88.35
106.91
121.91
Inventory Days
41.50
34.90
40.98
37.78
42.53
46.19
49.09
46.00
44.61
44.01
Payable days
127.64
117.80
109.36
81.80
71.83
85.02
86.62
87.50
128.12
130.71
Cash Conversion Cycle
-2.32
-1.16
23.27
35.04
45.47
36.35
56.09
46.86
23.40
35.22
Total Debt/Equity
0.67
1.31
1.63
1.67
1.22
-4.94
-19.21
2.17
0.81
0.45
Interest Cover
5.52
2.81
3.28
-1.91
16.06
0.39
-0.79
-0.94
0.00
0.35

Annual Reports:

News Update


  • Ambalal Sarabhai Enterprises gets nod to enter into SPA with Asence Pharma
    27th Nov 2020, 12:04 PM

    The company has received approval to enter into SPV for sale of 120446 and 85,446 equity shares

    Read More
  • Ambalal Sarabhai Enterprises’ JV gets permission to manufacture COVID-19 test with two target genes
    27th Nov 2020, 08:58 AM

    This is one more step towards commitment of providing diagnostic kits helpful in early diagnosis, evaluation and management of treatment

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.